RSV is the most common cause of hospitalization in babies, but Sanofi is one of a few companies producing a shot that can ...

Mortality was higher in the RSV cohort, with a 10.1% death rate, compared to 5.5% for flu. RSV infection showed a 52% higher ...

This builds upon its initial approval in May 2024 for adults aged 60 years and older, which makes mRESVIA the second approved ...

A virus that once filled pediatric hospital beds and terrified new parents is finally being pushed back—before babies are ...

A U.S. government scientist who oversees the team responsible for collecting data on COVID-19 and RSV hospitalizations used ...

The FDA has expanded the approval of mResvia to include active immunization in high-risk individuals 18 through 59 years of age.

The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 cause of hospitalization in infants.

The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on ...

The Iranian Foreign Minister Abbas Araghchi has condemned US strikes on the country’s nuclear facilities. He said Iran ...

The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...